Short Interest in Vor Biopharma Inc. (NASDAQ:VOR) Rises By 55,636.4%

Key Points

• Vor Biopharma Inc. experienced a dramatic increase in short interest, rising by 55,636.4% in July, reaching a total of 14,380,000 shares shorted as of July 15th.
• The stock is currently trading at $2.10 with a market cap of $262.42 million and a P/E ratio of -1.39.
• Analysts' ratings for Vor Biopharma are mixed, with one firm upgrading the stock to a "strong-buy" while another rated it a "strong sell."

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 14,380,000 shares, anincreaseof55,636.4% from the June 30th total of 25,800 shares. Currently,22.2% of the shares of the stock are sold short. Based on an average daily volume of 17,340,000 shares, the short-interest ratio is presently 0.8 days. Based on an average daily volume of 17,340,000 shares, the short-interest ratio is presently 0.8 days. Currently,22.2% of the shares of the stock are sold short.

Analysts Set New Price Targets

VOR has been the subject of a number of analyst reports. HC Wainwright raised shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. Wall Street Zen cut shares of Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th.

Vor Biopharma Trading Down 2.9%

VOR traded down $0.06 during trading on Monday, hitting $2.04. The company had a trading volume of 981,335 shares, compared to its average volume of 8,155,149. The stock has a market capitalization of $258.35 million, a P/E ratio of -1.35 and a beta of 2.06. Vor Biopharma has a one year low of $0.13 and a one year high of $3.29.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.